Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
123 EVENTS
The founder, Kyuzaburo Tomita, began full-scale research in Shizuoka on a manufacturing process using bittern as a raw material. His goal was to mass-produce magnesium carbonate for pharmaceutical use at good quality and low cost, hopeful to make it as a replacement for imported expensive products.
In the same year, he started manufacturing and selling cough medicine “Lauryl Sulfate Water” and “Lauryl Oil” from the Japanese evergreen oak, and invests all of the profits from the sales in researching the manufacturing process of magnesium carbonate.
Founder Kunizaburo Tomita began serious research in Shizuoka on a method using bitter juice as a raw material to mass-produce high-quality, inexpensive magnesium carbonate for medicinal use, which at the time relied on expensive imported products.
That same year, he manufactured and sold the cough suppressant 'Loriil Kels Water' and 'Loriil Oil' from Oobashi, investing all sales profits into research on the magnesium carbonate production method.
Moved in Shizuoka Prefecture in order to continue to procure bittern. He also began research into sodium carbonate, the main raw material for magnesium carbonate.
After repeated failures, they achieved the creation of magnesium carbonate, but it had less bulk than the intended result. The company attempted to market this product as “heavy magnesium carbonate” but it was not accepted in a market.
To procure bitter juice, he moved within Shizuoka Prefecture and also worked on research into the main raw material, sodium carbonate.
After repeated failures, the produced magnesium carbonate differed from the intended product and had low potency. It was sold as 'Heavy Magnesium Carbonate', but it was not accepted by the market.
Pure magnesium carbonate production was at last achieved after thorough review of the manufacturing process and development of equipments. Acetic acid, sulfuric acid, nitric acid, ether, and other chemicals and also under production.
By revising the process and developing machinery and equipment, the long-awaited pure magnesium carbonate production method was completed. Acetic acid, sulfuric acid, nitric acid, ether, and others were also produced.
Kyuzaburo (age 28) went to the Jishu salt fields (near the Seto Inland Sea) in search of a large amount of bittern. At that time, in the Jishu salt fields, after salt was extracted from seawater, the remaining bittern was discarded into the sea.
The factory operation in Kiga, Shizuoka failed in mass production and was closed, but the business and research continued.
At 28, Kunizaburo traveled to the Tokushū salt fields (near the Seto Inland Sea) to investigate large quantities of bitter juice. At that time, the Tokushū salt fields discarded the remaining bitter juice into the sea after extracting sea salt from seawater.
The factory in Shizuoka (Kiga) failed to achieve mass production and was closed, but the business and research continued.
Magnesium carbonate became official for British Pharmacopoeia and ether became officlal for US Pharmacopeia.
Magnesium carbonate obtained British Pharmacopoeia approval, and ether obtained U.S. Pharmacopoeia approval.
To secure bitter juice, a solar salt production facility was built in Hamana, Shizuoka Prefecture, and the business began, but securing the necessary land and the collapse of salt prices affected the main pharmaceutical business, so it was discontinued.
The Japanese Pharmacopoeia was enacted and promulgated (and went into effect the following year), and magnesium carbonate and magnesium sulfate were approved. It was touted that “the only domestic products that conformed to the pharmacopoeia were Tomita’s products.”
The credibility of the trademark “Ⓣ” mark increased, and demand for the product increased day by day. After years of struggling financially, Tomita was able to turn a profit.
Years later, Kyuzaburo was quoted as saying, “The heavens did not abandon the struggling man, but gave him a great boon. What was this boon? It was the enactment of the Japanese Pharmacopoeia in June of 1887.”
The Japanese Pharmacopoeia was promulgated (effective the following year), and magnesium carbonate and magnesium sulfate passed. It received praise: 'Among products that meet the Pharmacopoeia, the only domestic product is Tomita's.'
The trust in Tomita Pharmaceutical's trademark (Ⓣ) grew, and demand increased day by day. After years of hardship, profits were realized.
Later, Kunizaburo said, 'Heaven does not abandon those who toil hard, and indeed it bestowed a great blessing. What is that blessing? It is the promulgation of the Japanese Pharmacopoeia in June 1886 (Meiji 19).'
Just as the business was beginning to take off, the factory burnt down in a fire. The company lost not only its machinery but also all of its research materials, and had no choice but to cease operations.
Just as the business began to take off, the factory burned down completely. All machinery and research materials were lost, and the business was discontinued.
Re-examined the Jishu salt fields in the Setouchi area. Reached the conclusion that establishing a pharmaceutical plant in the Jishu salt fields would be an efficient way to secure bittern.
Re-examined the Tokushū salt fields. Concluded that establishing a pharmaceutical factory in the Tokushū salt field area would allow efficient securing of bitter juice.
Succeeded in separating and producing potassium chloride from bittern for the first time in Japan.
First in Japan to successfully separate and produce potassium chloride from bitter juice.
Kyuzaburo moved to Naruto, Tokushima Prefecture and built a factory in Seto-Cho (now Naruto City).
Kunizaburo moved to Naruto, Tokushima Prefecture, and built a factory in present-day Seto Town, Naruto City.
Established the 'Tomita Marine Salt Production Plant'. Began full-scale production of magnesium carbonate and magnesium sulfate.
Tomita Marine Products Industry was established on January 1. Full-scale production of magnesium carbonate and magnesium sulfate began.
Participates in the 4th National industrial Exhibition held in Kyoto. Here, Tomita showcased their magnesium carbonate, magnesium carbonate(heavy), magnesium sulfide, magnesium sulfate, potassium iodide, potassium bromide, sodium bromide, and sodium chloride.
A stone oven was used to extract salt from soil by boiling seawater in stone cauldrons. The salt was refined by removing the sodium sulfate contained within. It was named “Japanese salt” and sold.
The name of the company was changed to Tomita Pharmaceutical Factory.
Succeeded in separating and producing potassium chloride from bittern whose demand was increased due to Japan’s supply shortage after WWI.
Against the backdrop of shortages in national material procurement during World War I, successfully separated and produced potassium chloride from the bitter broth as demand rose.
Started focusing on the poduction of magnesium carbonate, potassium chloride, and bromine by reorganizing products line-up and establishing a new factory.
By reorganizing products and establishing a factory, focus on the production of magnesium carbonate, potassium chloride, and bromine.
Responding to increased demand for magnesium carbonate due to the development of the rubber industry, successfully produced magnesium carbonate for transparent rubber processing.
After WWI, the production of sodium chloride, which was rapidly in short supply, was started with the permission of recrystallized salt production.
After World War I, obtained special permission No.1 to resume production of sodium chloride, which had become rapidly scarce, and began manufacturing.
The invention of the concrete assembly-type Numai-dai (swamp well platform) contributed to the improvement of salt manufacturing technology in the Irihama typesalt fields*, and a subsidy was granted to the company for promoting the propagationand industrial development of the industry.
The devised concrete modular pond platform contributed to improving salt production technology in the Nibahama-style saltworks, leading to the award of a promotion of industry grant.
Kyuzaburo (age 76) left for an 8-month tour of Germany for pharmaceutical research.
Kusaburo departed for an eight-month Western inspection (Germany) for pharmaceutical research. Kusaburo (76 years old).
In response to the postwar recession, Kyuzaburo researched magnesium carbonate manufacturing methods. He succeeded in the industrialization of a manufacturing method of utilizing caustic lime as a starting material, and also perfected the manufacturing method for magnesium oxide.
In response to the post-World War I recession, researched the production method of magnesium carbonate. Successfully industrialized the lime-based method and completed the production method for magnesium oxide.
Tomita Pharmaceutical Factory was reorganized into a corporation and establishes itself as Tomita Seiyakusho Co.,Ltd.
Reorganized the Tomita Pharmaceutical Factory into a corporate organization and established 'Tomita Pharmaceutical Co., Ltd.'
Sales of the health conditioning agent Robaston.
Responding to the issuance of the “Order for Control of Daily Necessities,” the product of “bittern potassium salt” was sold as a fertilizer. Production was discontinued three years later due to Strategic Industries Control Act of the bittern industry.
A ceremony commemorating Tomita’s 50th anniversary was held at the newly renovated magnesium sulfate plant.
Received an order from the Navy to produce strontium.
Received an order from the navy to produce strontium.
The company began marketing vaccines for oral dysentery, typhoid, and paratyphoid, as well as an injectable vitamin B2 and the prophylactic drug penicillin.
The four large chimneys that had served as a symbol of the company were removed from its building during the war for fear that they would be used as air raid markers.
Sold oral dysentery vaccine, typhoid vaccine, paratyphoid vaccine, as well as injectable vitamin B2 and preventive penicillin.
The four large chimneys that were the company's symbol were removed due to concerns that they would serve as targets during wartime air raids.
Established 'Tomita Pharmaceutical Co., Ltd.' with Tomita Sadazaburo as representative director.
The Nankai Earthquake in 1946.
In 1947, the company began marketing “Macron tablets,” an anthelmintic with an active ingredient of seaweed extract.
A fire at a magnesium carbonate drying plant in 1948.
Using by-products from textile mills, the company began producing anhydrous sodium sulfate in 1949.
A fire at a salt brine refinery in 1949.
Typhoon Jane in 1950.
During this five-year period, the company researched and developed a wide range of products for which it was licensed to manufacture, including barium chloride, camphor oil injection, barium sulfate, Ringer’s solution, saline solution, vitamin B2 injection solution, and saline tablets.
Using by-products from textile mills, the company began producing sodium sulfide in 1951.
Tomita Pharmaceutical Co., Ltd. was established on July 8 (using the current Japanese name), with Teizaburo Tomita as representative director.
The company was affected by the bankruptcy of its main customers and the resulting dishonored check. Even during the high-growth period of the Japanese economy, Tomita’s business conditions remained tense.
As a challenge in a new field, the company developed and sold an organic hair straightening agent, “Ammonium Thioglycolate.”
Magnesium silicate was developed and marketed as an antacid.
Developed high-purity magnesium oxide for silicon steel sheets.
Suffered severe damage from the second Muroto typhoon. Production of “Ammonium Thioglycolate” was discontinued due to damage to the manufacturing equipment caused by the second Muroto Typhoon.
Started trade with Korea and Taiwan.
The company developed aluminum hydroxide gel and synthetic aluminum silicate in order to enter the field of antacid agents in earnest.
Developed magnesium metasilicate aluminate as an antacid agent.
Started trade with Hong Kong, Vietnam, the Philippines, and Australia.
Management policy was formulated into a long-term plan under the guidance of Tanabe Management Counseling Center. Established “Company Policy,” “Creed,” and “Corporate Mission Statement.” A management policy presentation meeting was held, and the corporate structure was enhanced and improved.
Developed “Wakame Tea” using wakame seaweed, a specialty of Naruto City, and registered it as a trademark. However, the market response was weak and the company abandoned the commercialization of the product.
Succeeded in developing high-purity Sodium Chloride for use in artificial dialysis.
Developed and began sale of Uni-Meisui, a natural liquor clarifier made from carrageenan.
Established Tokushima Plant in Tokushima Pharmaceutical Industrial Park to strengthen facilities to meet increasing demand for antacids.
With the enactment of the “Pharmaceutical GMP” ministerial ordinance, the company worked to estabilish a quality system from the point of both management system and equipment control.
Research was initiated on the production of gluconic acid from mold fungi.
Started joint research with the Agency of Industrial Science and Technology and the Shikoku National Industrial Research Institute on pore size control technology for inorganic salts.
Started production and sale of the synthetic adsorbent TOMIX-AD and high-performance adsorbent Q-Fine series.
Tomita was contracted to produce powdered artificial seawater “Marine Art” in collaboration with Senju Pharmaceutical Co., Ltd.
Celebrated 100 years of business.
Celebrated its 100th anniversary.
Mass production of a powdered dialysate for overseas markets began.
Mass-produced powdered dialysis agents for overseas markets.
The first powdered dialysate production facility was completed.
Full-scale production began.
Completed Building 1 of the powdered dialysis agent facility.
Commenced full-scale production of powdered dialysis agents.
Launched sales of powdered dialysate KIDOLIME T-30.
Launched sales of the powdered dialysis agent 'Kidryum T-30'.
A second powdered dialysate production facility was completed.
A system to increase production was established.
Completed Building 2 of the powdered dialysis agent facility.
Established a scale-up system for powdered dialysis agent production.
Began operation of the Kawasaki Plant, a plant dedicated to the production of sodium chloride.
Completion of magnesium oxide production building.
Commenced operations of the Kawasaki plant, dedicated to sodium chloride production.
Magnesium oxide production building completed.
Opened a representative office in New Jersey, USA.
Completion of a manufacturing plant dedicated to the production of FLORITE®.
New Jersey U.S. branch office established.
Fluorite-specific manufacturing plant completed.
Tomita R&D Center was completed. Tomita focused on the development of new products as an R&D-oriented company.
Tomita R&D Center completed. Focused on new product development as a research and development company.
A third powdered dialysate production facility was completed.
Powder dialysis agent Building 3 completed.
Compliance Policy and Action Guidelines were established, as well as the Compliance Committee.
Compliance basic policy and code of conduct established.
Compliance Committee established.
A new QC center was established, strengthening sales of pharmaceutical raw materials to overseas customers.
Established QC Center and strengthened overseas pharmaceutical raw material sales.
Quality Policy was established.
Quality policy established.
Committed to compliance with laws and making products with quality as the top priority.
§07
News
9 ARTICLES
Tomita Pharmaceutical Selected for Wage Increase Support Grant in Fifth Public Offering
Tomita Pharmaceutical Co., Ltd. has been selected for the Ministry of Economy, Trade and Industry's "Large-Scale Growth Investment Subsidy for Labor Efficiency and Wage Increase for Medium and Small Enterprises and Startups" in its fifth public offering. The grant will invest in factory restructuring projects for dialysis solutions, pharmaceutical raw materials, and other products, aiming to raise the average employee wage increase rate to 7.0%.
Announcement of Participation in AAPS 2026 PHarmSCi 360
Futamura Pharmaceutical will exhibit at the AAPS 2026 PHarmSCi 360 held in New Orleans, USA, from October 25 to 28, 2026. During the event, we will introduce our product lineup, technologies, and solutions. The venue is the Ernest N. Morial Convention Center, and our booth number is 1436.
Announcement of participation in Food Development Expo 2026
Futamata Pharmaceutical will exhibit at Food Development Expo 2026, held at Tokyo Big Sight from October 14 to 16, 2026. We will introduce nutrition-enhancing products and technologies such as Fluorite and Fersoob, and demonstrate at Booth A-034. Presentations on the functional aspects of Fluorite will be conducted on October 14 and 15.
Announcement of Participation in CPHI Milan 2026
Futamura Pharmaceutical Co., Ltd. will exhibit at CPHI Milan 2026, held at Fiera Milano in Milan, Italy, from October 6 to 8, 2026. At Booth 3D51 in Hall 3, we will showcase our product lineup, technology, and services.
International Sales Department Osaka Office Headquarters Relocation
In order to strengthen overseas business structure and enhance internal collaboration, the Osaka Office of the International Sales Department of the Sales Headquarters will be relocated to the headquarters. The start date of operations at the new location is October 1, 2026.
Interview of Research Staff Published in Tokushima Shimbun
An interview with Takashi Takemoto, a research staff member of the Research Headquarters, was published in the April 11, 2026 edition of the Tokushima Shimbun morning paper titled "Challenge and Growth." The article introduces his research experience in graduate school, the circumstances that led him to pursue inorganic chemistry after joining the company in 2021, and his current work on developing drugs for kidney diseases. It also highlights the environment where he can be involved in everything from market research to manufacturing and analysis, and discusses the rewards of research.
Announcement of Participation in CPHI Frankfurt
Futamura Pharmaceutical Co., Ltd. will exhibit at CPHI Frankfurt, which will be held at Messe Frankfurt in Germany from Tuesday, October 28, 2025, to Thursday, October 30, 2025. Booth number is 11.0B24.
Exhibiting at Food Development Exhibition 2025
Tomita Pharmaceutical will exhibit at Food Development Exhibition 2025, held at Tokyo Big Sight from October 15 to 17, 2025. The company will introduce functional powders, nutritional enrichment products, and its technologies. The booth is A-034 in the Atrium Hall.
Naming Rights Agreement with Naruto University of Education
Futamura Pharmaceutical has entered into a naming rights agreement with the National University Corporation Naruto University of Education, and the facility’s nickname became “Futamura Pharmaceutical Manabi Library.” The contract period is from June 1, 2025 to March 31, 2028. As part of its community contribution activities, the company intends to actively participate and cooperate in future opportunities and events.
§08
Public records
GOV
National Tax Agency basic information1480001005057
Source: National Tax Agency Corporate Number Publication Site, basic three items